Related Experiment Video
Updated: Oct 2, 2025
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
An update on the safety of olaparib for treating ovarian cancer
Kelsi Cottrell1, Caroline L Clark1, Richard T Penson1
1Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Introduction:
PARP inhibitors have dramatically improved outcomes for ovarian cancer patients, transforming oncologists' armamentarium and fueling hope for more cures and longer survival.
Areas Covered:
The recent PARP inhibitor randomized trials of FDA approved PARP inhibitors for ovarian cancer, olaparib, rucaparib and niraparib, and implications for clinical care are discussed with a focus on toxicity and risks. PARP adds NAD polymers to DNA-binding proteins, improving survival of cells after DNA damage, and acting as a scaffold for important DNA Damage Response (DDR) enzymes. If this system is inhibited, PARP activation cannot support DNA repair when there is synthetic lethality from BRCA mutations or homologous repair dysfunction (HRD), and the accumulation of DNA damage can kill cancer and lead to the catastrophic complications of MDS/AML. Although the risk of AML can be a < 1% risk, the incidence of MDS/AML presently approaches 10% in patients with BRCA mutations, multiple prior lines of platinum therapy, and protracted exposure to PARP inhibitors.
Expert Opinion:
PARP inhibitors are a well-tolerated and exciting new class of agents that improve survival despite the risk of AML. Understanding of the biology has led to optimal use and potential new strategies for overcoming PARP resistance.
Insights
PARP inhibitors improve ovarian cancer survival but carry a risk of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). Understanding PARP inhibitor biology aids optimal use and resistance management.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- PARP inhibitors have significantly enhanced treatment outcomes for ovarian cancer patients.
- These agents offer improved survival rates and represent a major advancement in oncological therapy.
Purpose of the Study:
- To review recent randomized trials of FDA-approved PARP inhibitors (olaparib, rucaparib, niraparib) for ovarian cancer.
- To discuss the clinical implications, focusing on toxicity and risks associated with their use.
Main Methods:
- Discussion of PARP inhibitor mechanisms, including their role in DNA repair and synthetic lethality in BRCA-mutated or HRD-positive cancers.
- Analysis of randomized trials and clinical data concerning efficacy, toxicity, and risk of MDS/AML.
Main Results:
- PARP inhibitors are effective in improving survival for ovarian cancer patients.
- A significant risk of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) exists, particularly in patients with BRCA mutations, prior platinum therapy, and prolonged PARP inhibitor exposure, with incidence approaching 10%.
Conclusions:
- PARP inhibitors are a valuable, generally well-tolerated class of drugs for ovarian cancer, improving survival despite the associated risk of MDS/AML.
- Further understanding of PARP inhibitor biology is crucial for optimizing treatment strategies and addressing resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:34Inhibition of Cdk Activity